Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

The global insulin pumps market, valued at USD 5.5 billion in 2022, is poised for remarkable growth, with an anticipated ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Embecta said its patch pump was designed with feedback from people with Type 2 diabetes. The company presented data in June finding that 200-unit reservoirs have enough capacity for only 38% of adults ...

A series of case reports to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes ...

In April, Medtronic obtained FDA approval for another new product, Inceptiv, a spinal cord stimulator for treating chronic pain. The device can automatically adjust the therapy — a unique feature — to ...

Implanting a pouch of stem-cell-derived pancreas cells under the skin of type 1 diabetics has enabled them to live without ...

Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated with insulin pump therapy, new research reveals today. The study presented ...

Diabetics who fly with an insulin pump could find themselves with lower-than-normal blood sugar levels, a new study sa ...